Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma

November 11, 2022

https://www.globenewswire.com/news-release/2022/11/11/2554350/0/en/Candel-Therapeutics-Announces-Late-Breaking-Oral-Presentation-at-SITC-Annual-Meeting-with-Data-on-CAN-2409-in-Combination-with-Nivolumab-in-a-Phase-1-Mechanistic-Clinical-Trial-in-.html

NEEDHAM, Mass., Nov. 11, 2022 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Nasdaq:CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced presentation of late-breaking data from a phase 1 mechanistic clinical trial of CAN-2409, Candel’s lead viral immunotherapy in development, in combination with nivolumab and standard of care treatment in patients with high-grade glioma. Data were presented at the 37th Annual Meeting of Society for Immunotherapy of Cancer (SITC) today in Boston.

Read more at globenewswire.com

Related news for (CADL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.